Nephros Inc. (NASDAQ:NEPH) Short Interest Down 49.9% in December

by · The Cerbat Gem

Nephros Inc. (NASDAQ:NEPH – Get Free Report) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totaling 3,625 shares, a decline of 49.9% from the November 30th total of 7,233 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 67,084 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 67,084 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Analyst Ratings Changes

NEPH has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Nephros to a “strong-buy” rating in a report on Saturday, October 18th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Nephros currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

View Our Latest Research Report on Nephros

Nephros Stock Down 5.7%

Shares of NEPH traded down $0.30 during trading on Friday, reaching $4.93. The company’s stock had a trading volume of 20,894 shares, compared to its average volume of 57,515. The company has a fifty day moving average of $5.11 and a two-hundred day moving average of $4.46. Nephros has a twelve month low of $1.39 and a twelve month high of $6.42. The company has a market cap of $52.41 million, a price-to-earnings ratio of 37.93 and a beta of 1.48.

Nephros (NASDAQ:NEPH – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The business had revenue of $4.76 million during the quarter, compared to analyst estimates of $3.87 million. Nephros had a net margin of 8.26% and a return on equity of 15.81%.

Hedge Funds Weigh In On Nephros

Several large investors have recently modified their holdings of NEPH. Dimensional Fund Advisors LP acquired a new position in Nephros in the third quarter worth about $64,000. Citadel Advisors LLC lifted its holdings in Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after buying an additional 4,655 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Nephros by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after acquiring an additional 2,898 shares in the last quarter. Finally, Topline Capital Management LLC grew its position in shares of Nephros by 13.1% in the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after acquiring an additional 55,360 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

(Get Free Report)

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.

Further Reading